Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 15 Jun 2002

Kaiser Rolf, Sezer Orhan, Papies Anja, Bauer Steffen, Schelenz Claudia, Tremblay Pierre-Benoit, Possinger Kurt, Roots Ivar, Brockmöller Jürgen

Abstract excerpt

PURPOSE: The use of serotonin 5-hydroxytryptamine type 3 receptor antagonists has substantially reduced, but not eliminated, nausea and vomiting in cancer chemotherapy. This study sought to investigate whether efficacy of antiemetic treatment with ondansetron and tropisetron depends on cytochrome P-450 2D6 (CYP2D6) genotype, hypothesizing that the rapid and particularly the ultrarapid metabolizers of these drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Nausea

Share to Polymorphism, Restriction Fragment Length

Share to Predictive Value of Tests

Share to Serotonin Antagonists

Share to Vomiting

Source

Identifiers

PMID: 12065557
DOI: 10.1200/JCO.2002.09.064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.PMID 12065557Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline forCYP2D6genotype and use of ondansetron and tropisetronSemantic proximity Read ↗

Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Semantic proximity Read ↗

CYP2D6 genotype and associated 5-HT3 receptor antagonist outcomes: A systematic review and meta-analysis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update.Semantic proximity Read ↗

Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.Semantic proximity Read ↗

The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogeneticsSemantic proximity Read ↗

Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.Semantic proximity Read ↗

A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Semantic proximity Read ↗

Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.Semantic proximity Read ↗

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Semantic proximity Read ↗

CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting.Semantic proximity Read ↗

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.